Related Experiment Video
Updated: May 20, 2026

Purification of a High Molecular Mass Protein in Streptococcus mutans
Published on: September 14, 2019
[Optimizing expression and antibody preparation of recombinant Streptococcus mutans surface protein]
Jie Jin1, Mingwen Fan, Yuhong Li
1Dept. of Operative Dentistry and Endodontics, Stomatological Hospital of Hangzhou, Hangzhou 310006, China.
Recombinant Streptococcus mutans surface protein (rPAc) was successfully expressed in E. coli. A specific polyclonal antibody against rPAc was prepared, aiding further research in inoculation methods.
Area of Science:
- Microbiology
- Molecular Biology
- Immunology
Background:
- Streptococcus mutans is a key pathogen in dental caries.
- The surface protein rPAc plays a role in S. mutans virulence.
- Efficient expression systems are needed for studying bacterial surface proteins.
Purpose of the Study:
- To optimize the soluble expression of recombinant Streptococcus mutans surface protein (rPAc) in Escherichia coli.
- To generate a specific polyclonal antibody against rPAc.
Main Methods:
- Optimized culture conditions for rPAc expression in E. coli.
- Purified rPAc was used to immunize mice for polyclonal antibody production.
- Western blot and ELISA were employed to validate antibody specificity and titer.
Main Results:
- Maximal soluble rPAc expression achieved in Luria-Bertani medium (pH 7.2) at 30°C with 1.0 mmol/L IPTG induction.
- The resulting antiserum showed a high titer of approximately 1:6000 via ELISA.
- Western blot confirmed the specific recognition of rPAc by the antibody.
Conclusions:
- Effective soluble expression of rPAc in E. coli was demonstrated.
- A high-specificity polyclonal antibody against rPAc was successfully prepared.
- These findings support further investigation into DNA prime-protein boost inoculation strategies.
More Related Videos
13:53Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022